Document Detail

Valproic acid as a therapy for adenomyosis: a comparative case series.
MedLine Citation:
PMID:  20601534     Owner:  NLM     Status:  MEDLINE    
Adenomyosis is a difficult disease to manage and currently there is no investigative drug for adenomyosis on the horizon. We have previously reported in a pilot study that valproic acid (VPA) appears to be effective in treating adenomyosis. In this case series, we further evaluated the efficacy of VPA, with or without a progestin-containing intrauterine device, in the treatment of patients with adenomyosis. We recruited 12 patients with confirmed adenomyosis who complained of dysmenorrehea and had enlarged uterus. All patients took VPA for 3 months, then randomly assigned to 2 groups, 1 receiving no further treatment and the other were inserted with a levonorgestrel-releasing intrauterine system (Mirena) and were followed up for an additional 3 months. The primary outcome measures were the severity of dysmenorrhea and uterine size. Both measures were evaluated prior to the drug treatment and 3 and 6 months after the drug treatment, respectively. We found that VPA treatment resulted in complete resolution of dysmenorrhea and an average reduction in uterine size by 26% 6 months after the treatment, regardless of whether Mirena was used or not. Moreover, the amount of menses decreased significantly. Thus, VPA appears to be well tolerated and a promising drug for treating adenomyosis.
Xishi Liu; Lei Yuan; Sun-Wei Guo
Related Documents :
12506304 - Coasting. a viable option for patients at risk of ovarian hyperstimulation syndrome.
20436264 - Efficacy of recombinant human follicle stimulating hormone at low doses in inducing spe...
7921394 - Treatment of endometriosis by carbon dioxide laser during gamete intrafallopian transfer.
1308424 - Danazol. a new perspective in the treatment of htlv-1 associated myelopathy (preliminar...
15995434 - Acetabular augmentation ring for recurrent dislocations in revision arthroplasty.
1098874 - Vibramycin in paediatrics. an evaluation of the onset of action and efficacy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-07-02
Journal Detail:
Title:  Reproductive sciences (Thousand Oaks, Calif.)     Volume:  17     ISSN:  1933-7205     ISO Abbreviation:  Reprod Sci     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-21     Completed Date:  2010-12-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101291249     Medline TA:  Reprod Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  904-12     Citation Subset:  IM    
Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai Medical College, 419 Fangxie Road, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dysmenorrhea / drug therapy*
Endometriosis / drug therapy*
Intrauterine Devices, Medicated
Levonorgestrel / administration & dosage*
Organ Size
Pain Measurement
Random Allocation
Uterus / drug effects*
Valproic Acid / therapeutic use*
Reg. No./Substance:
797-63-7/Levonorgestrel; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessing speech intelligibility in children with hearing loss: toward revitalizing a valuable clini...
Next Document:  Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitu...